In a patient receiving 200 mg intramuscular testosterone weekly with a serum testosterone of 633 ng/dL and a hematocrit of 51.6%, when should a urology referral be made?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Urology Referral Recommendations for Testosterone Therapy

In your patient with testosterone 633 ng/dL and hematocrit 51.6% on 200 mg IM weekly, you should refer to urology if PSA increases >1.4 ng/mL within 12 months of starting treatment, if PSA rises above 4.0 ng/mL at any time, or if there is an abnormal digital rectal examination. 1

Prostate Monitoring Thresholds

The 2018 Endocrine Society guideline provides the most current and authoritative criteria for urological consultation 1:

  • PSA increase >1.4 ng/mL within the first 12 months of testosterone initiation
  • Confirmed PSA >4.0 ng/mL at any point during treatment
  • Abnormal findings on digital rectal examination
  • Substantial worsening of lower urinary tract symptoms

An older but still relevant 2004 NEJM guideline suggests a more aggressive monitoring approach, particularly during the first year when occult cancers may theoretically grow more rapidly with testosterone normalization 2. This approach recommends urologic referral for:

  • PSA increase >1.0 ng/mL during the first 6 months of treatment
  • PSA increase >0.4 ng/mL per year thereafter

The more conservative 2018 Endocrine Society threshold of 1.4 ng/mL in 12 months represents current standard practice, though clinicians may reasonably adopt the stricter 2004 criteria for higher-risk patients 2, 1.

Hematocrit Management

Your patient's hematocrit of 51.6% requires immediate attention but does not necessitate urology referral—this is a primary care management issue:

Stop testosterone therapy when hematocrit exceeds 54% 1. At 51.6%, your patient is approaching but has not yet reached this threshold.

Immediate Actions for Elevated Hematocrit:

  1. Evaluate for secondary causes: Check for hypoxia and sleep apnea 1
  2. Consider dose reduction: The 200 mg weekly regimen is unusually high and likely contributing to the elevated hematocrit
  3. Adjust injection frequency: Research demonstrates that 200 mg every 2 weeks (not weekly) causes significantly more erythrocytosis than 100 mg weekly 3

Your patient is receiving double the typical dose (200 mg weekly vs. the standard 200 mg every 2-4 weeks per FDA labeling 4). This explains both the elevated testosterone level and rising hematocrit. Men receiving 200 mg biweekly have an 8% risk of hematocrit >54%, compared to only 1% with 100 mg weekly 3.

Recommended Dose Adjustment:

Reduce to 100 mg weekly or 200 mg every 2 weeks to maintain therapeutic testosterone levels while minimizing erythrocytosis risk 3. The current testosterone level of 633 ng/dL is already in the mid-normal range, so dose reduction is appropriate 1.

Monitoring Schedule

For men 40-69 years old receiving testosterone therapy 1:

  • Baseline: PSA and digital rectal examination before starting
  • 3-12 months: Repeat PSA and examination
  • Annually thereafter: Continue screening per age-appropriate guidelines
  • Hematocrit: Check at 3-6 months, then annually 1

Common Pitfalls

Do not confuse hematocrit management with urology referral criteria. Elevated hematocrit is managed by stopping or reducing testosterone and evaluating for hypoxia/sleep apnea—not by referring to urology 1. Urology referral is specifically for prostate-related concerns: PSA changes or abnormal examinations.

Do not continue current dosing. Your patient's regimen of 200 mg weekly is excessive and directly contributes to the elevated hematocrit. This dose should be reduced regardless of the hematocrit level 4, 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.